2021 Archives
 

Still Protected! Medicare's Six Protected Drug Classes Policy Survives Trump's Attack

ADAP Advocacy Association | April 29, 2021

Revisions to the Trogarzo (ibalizumab-uiyk) product labeling

FDA | April 26, 2021

CANN Celebrates Biden Administration Protecting Medicare Part D

Community Access national Network | March 2021

Certain HIV Meds May Trigger Weight Gain 

WebMD | March 16, 2021

Gilead and Merck Announce Agreement to Jointly Develop and Commercialize Long-Acting, Investigational Treatment Combinations of Lenacapavir and Islatravir in HIV

Business Wire | March 15, 2021

Another HIV Tivicay Birth Outcome: Better Infant Survival 

Medscape | MARCH 15, 2021

PAF’s Co-Pay Relief Expands Assistance to Cover Insurance Premiums (including HIV/AIDS Fund).

ADAP | MARCH 11, 2021

CROI: GILEAD'S INVESTIGATIONAL LENACAPAVIR DEMONSTRATES SUSTAINED LONG-ACTING EFFICACY THROUGH WEEK 26 IN DATA PRESENTED AT CROI
NATAP | CROI 2021 March 6-10
CROI: PHASE IIA PROOF-OF-CONCEPT TRIAL OF NEXT-GENERATION MATURATION INHIBITOR GSK3640254
NATAP | CROI 2021 March 6-10
CROI: GSK3640254 IS A NOVEL MATURATION INHIBITOR WITH AN OPTIMIZED VIROLOGY PROFILE
NATAP | CROI 2021 March 6-10
CROI: NNRTI MK-8507 SELECTS V106 MUTATIONS, ACTIVE AGAINST COMMON NNRTI MUTATIONS
NATAP | CROI 2021 March 6-10
   
CROI: CLINICAL EVALUATION OF DRUG INTERACTIONS WITH ORAL LENACAPAVIR AND PROBE DRUGS
NATAP | CROI 2021 March 6-10
CROI: ACTIVITY AND RESISTANCE CHARACTERIZATION OF THE HIV CAPSID INHIBITOR LENACAPAVIR
NATAP | CROI 2021 March 6-10
CROI: POTENT ANTIVIRAL ACTIVITY OF LENACAPAVIR IN PHASE 2/3 IN HEAVILY ART-EXPERIENCED PWH
NATAP | CROI 2021 March 6-10

Revisions to TRIUMEQ and DOVATO labeling

FDA | March 2, 2021

Op-ed: Six Protected Classes and Protecting People with HIV

plus | February 26, 2021

ViiV Healthcare Submits Supplemental New Drug Application to US FDA for Expanded Use of Cabenuva (cabotegravir, rilpivirine) as an HIV Treatment for Use Every 2-Months

ViiV Healthcare | February 24, 2021

Ask the Doctors: New HIV treatment administered monthly 

Lompoc Record | February 18, 2021

FDA Approves Cabenuva and Vocabria for the Treatment of HIV-1 Infection

ViiV Healthcare | January 21, 2021

MAT Provides Patients with More Transparency Around Medicine Costs

ADAP Advocacy Association | January 21, 2021

Emma Berry, Advocacy & Strategic Alliances, Pharmaceutical Research and Manufacturers of America (PhRMA).

Tivicay approved in Europe in new dispersible tablet for children with HIV 

pharmaphorum | January 14, 2021

Valganciclovir and Ganciclovir Effective for HIV-Associated CMVR in Low- and Middle-Income Countries

Infectious Disease Advisor | January 11, 2021

Many health plans now must cover full cost of expensive HIV prevention drugs 

Duluth News Tribune | January 10, 2021